• contact us navContact Us
  • search navSearch
Let's connect

Want to discuss your project or have any questions?

Lung disease models

Expert solutions for pulmonary research

According to the World Health Organization (WHO), lung diseases are the second leading cause of death worldwide, and their significance is expected to increase over the next 20 years. Our company provides clinically relevant in vivo and ex vivo lung disease models, including pulmonary fibrosis and asthma. Our expert scientists utilise their expertise to design and conduct studies tailored specifically to the needs of our clients, supporting respiratory discovery programs effectively.

Pulmonary research lab at Nuvisan

Lung fibrosis in vivo: clinically relevant models for drug discovery

Our lung fibrosis in vivo models offer a comprehensive approach to studying pulmonary fibrosis, a chronic and progressive lung disease. Using bleomycin-induced models, we simulate human lung fibrosis to assess the potency and anti-fibrotic efficacy of candidate compounds through clinically relevant pulmonary function parameters and histopathology readouts. Test compounds can be administered via various routes, including oral, subcutaneous and intranasal, with Nintedanib used as a standard-of-care reference for comparative analysis.

Lung fibrosis ex vivo: precision cut pulmonary slice (PCPS) models

Our lung fibrosis ex vivo models utilise precision cut pulmonary slices (PCPS), three-dimensional tissue explants derived from human or animal lungs. These models preserve the anatomical architecture and specific features of lung tissue, enabling comparative testing across various experimental conditions. PCPS models closely mimic in vivo conditions, making them invaluable for toxicological and pharmaceutical research, and serving as an effective alternative to traditional animal models in compound screening.

 

Image of Precision Cut Pulmonary Slices (PCPS) model 

Asthma in vivo: preclinical models for drug discovery

Our asthma in vivo models offer a comprehensive approach to studying this complex and heterogeneous chronic inflammatory disease. We provide two distinct mouse models of house dust mite (HDM)-induced asthma, representing either eosinophilic or mixed-granulocytic asthma. These models enable the profiling of anti-inflammatory candidate compounds against standard-of-care treatments, with administration options including oral, subcutaneous and intranasal routes.

 

Image of eosinophilic HDM-induced asthma model 

 
v.1.1.1203